All > Stem Cell Transplant > Transplant

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Multiple MyelomaAllogeneic Hematopoietic Stem Cell Transplantation - Procedure
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying a reduced intensity conditioning regimen as a treatment for relapsed multiple myeloma.

Eligible Conditions
  • Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Hematopoietic Cell Transplantation
1
Busulfan
1
Allogeneic Hematopoietic Stem Cell Transplantation

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: Up to 2 years post-transplant

Day 365
Rate of minimal residual disease-negativity
Year 1
1-year cumulative incidence TRM
Year 2
2-year cumulative incidence of TRM
Day 100
100-day cumulative incidence of treatment-related mortality (TRM)
Year 2
Overall survival (OS)
Year 2
Rate of relapse
Year 1
1- year GVHD-free Relapse-free Survival (GRFS)
Year 2
2-year progression-free survival (PFS)
Year 2
Best response rate
Incidence of adverse events
Overall response rate
Up to 6 weeks
Cumulative incidence of grade II-IV acute graft-versus host disease (GvHD (aGVHD)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Hematopoietic Cell Transplantation
1
Busulfan
1
Allogeneic Hematopoietic Stem Cell Transplantation

Side Effects for

Treatment (Fludarabine, Transplant, Immunosuppression)
5%Febrile neutropenia
5%Hypoxia
5%Acute kidney injury
4%Blood bilirubin increased
4%Creatinine increased
4%Diarrhea
4%Sepsis
3%Bronchopulmonary hemorrhage
3%Chronic kidney disease
3%Hypotension
3%Lung infection
3%Left ventricular systolic dysfunction
3%Thromboembolic event
1%Gastric hemorrhage
1%Atrial fibrillation
1%Atrial flutter
1%Heart failure
1%Mucositis oral
1%Pleural effusion
1%Syncope
1%Multi-organ failure
1%Typhlitis
1%Respiratory failure
1%Treatment related secondary malignancy
1%Fever
1%Ejection fraction decreased
1%Paroxysmal atrial tachycardia
1%Gastritis
1%Hemolytic uremic syndrome
1%Ascites
1%Encephalitis infection
1%Hemolysis
1%Myalgia
1%Small intestine infection
This histogram enumerates side effects from a completed 2019 Phase 2 trial (NCT01251575) in the Treatment (Fludarabine, Transplant, Immunosuppression) ARM group. Side effects include: Febrile neutropenia with 5%, Hypoxia with 5%, Acute kidney injury with 5%, Blood bilirubin increased with 4%, Creatinine increased with 4%.

Trial Design

1 Treatment Group

Treatment (conditioning regimen, stem cell transplant)
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Allogeneic Hematopoietic Stem Cell Transplantation · No Placebo Group · Phase 2

Treatment (conditioning regimen, stem cell transplant)Experimental Group · 7 Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, Fludarabine, Daratumumab, Cyclophosphamide, Mycophenolate Mofetil, Melphalan · Intervention Types: Procedure, Drug, Drug, Biological, Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Allogeneic Hematopoietic Stem Cell Transplantation
2012
Completed Phase 2
~1280
Tacrolimus
FDA approved
Fludarabine
FDA approved
Daratumumab
FDA approved
Cyclophosphamide
FDA approved
Mycophenolate mofetil
FDA approved
Mechlorethamine
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years post-transplant

Who is running the clinical trial?

Srinivas DevarakondaLead Sponsor
Srinivas Devarakonda, M.D.Principal Investigator - Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center

Eligibility Criteria

Age 18 - 75 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have an estimated creatinine clearance of greater than 40 mL/minute.
You are a haploidentical, mismatch or matched related or unrelated donor.
You have had a partial response (PR) or better prior to allo-transplantation.
You have relapsed MM with chemo sensitivity disease, with or without prior autologous HSCT.
ALT/AST < 2.5 x the upper normal limit.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top